BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

OCGN upcoming catalysts

Ocugen: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to OCGN (.ics).

Drugs: Sub-Retinal Administration of OCU400-301

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-02-12 est.P3Ocugen OCGNNCT06388200 A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaRetinitis Pigmentosaactive not recruiting140

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-28 est.P2/P3Ocugen OCGNNCT05956626 A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseStargardt Diseaseactive not recruiting51
2026-02-03P1/P2Ocugen OCGNNCT06018558 Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyGeographic Atrophyactive not recruiting60

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.